NEW DELHI: The Drug Controller General of India (DCGI) has given nod to Bharat Biotech to conduct phase-3 trials for its COVID-19 intra-nasal vaccine (BBV154), reports said on Friday.
According to Bharat Biotech, the trials would evaluate the nasal vaccine for both the two-dose primary schedule and also to use as a booster dose schedule.
Ready for a challenge? Click here to take our quiz and show off your knowledge!
BBV154 (nasal covid vaccine) has received approval for phase-3 clinical trials.
The trials will evaluate BBV154 nasal vaccine for both the two-dose primary schedule and booster dose schedule.
An intranasal vaccine would not only be simple to administer but also reduce the use of needles and syringes, among others.
Ready for a challenge? Click here to take our quiz and show off your knowledge!
It would also impact the overall cost of a vaccination drive, Bharat Biotech’s chairman Krishna Ella had said.